Update shared on 16 Nov 2025
Analysts have raised their price target for Shilpa Medicare to ₹514.5. This update is supported by improved growth and profitability projections, which offset a slightly higher discount rate and lower expected future P/E.
What's in the News
- Shilpa Medicare successfully completed its fourth complex clinical program, SMLINJ011, achieving positive topline Phase 3 results for OERIS™ (Ondansetron Extended-Release Injection). The therapy is aimed at improving prophylaxis of chemotherapy-induced nausea and vomiting. Results showed an 89% complete response rate in the OERIS™ arm compared to 82% for standard therapy, with no serious or severe adverse events reported (Key Developments).
- The Board of Directors scheduled a meeting on November 13, 2025, to approve the unaudited financial results for the second quarter and half year ended September 30, 2025 (Key Developments).
- An Extraordinary Shareholders Meeting was held on November 8, 2025, via postal ballot. The agenda included discussion of the reclassification of Suraj Kumar Inani and Priya Inani from the "Promoter group" category to the "Public" category (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at ₹514.5.
- The Discount Rate has risen slightly from 12.73% to 12.76%.
- The Revenue Growth projection has increased from 23.53% to 25.94%.
- The Net Profit Margin estimate has grown from 25.39% to 26.93%.
- The Future P/E expectation has fallen from 22.71x to 20.00x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.